ImmunoPrecise Antibodies Ltd. Unveils Presentation Highlighting Advances in AI-Driven Drug Discovery and Biotherapeutics

Reuters

2025/06/18

ImmunoPrecise Antibodies Ltd. Unveils Presentation Highlighting Advances in AI-Driven Drug Discovery and Biotherapeutics

ImmunoPrecise Antibodies Ltd. has presented its latest advancements and financial highlights. The company is a leading provider of biotherapeutic research and technology services, with a focus on antibody discovery and development. Notably, ImmunoPrecise has partnered with 19 of the top 20 global pharma companies and holds 25 patents. The company boasts a strong financial standing with C$12.9M in cash and no debt, maintaining a low burn rate of approximately C$1.2M per quarter. BioStrand, a part of ImmunoPrecise, has demonstrated rapid revenue growth and high gross margins, significantly contributing to the company's overall performance. The LENSai platform, acquired through BioStrand, enhances capabilities in developing new therapies and diagnostics, offering advanced data analysis and optimization of antibody sequences. The platform's HYFT technology further improves data processing efficiency, searching through extensive multi-omics databases at unprecedented speeds. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief on June 18, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2544970408"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544970408\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544970408?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-18 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544970408","market":"nz","top_or_hot":-1,"title":"ImmunoPrecise Antibodies Ltd. Unveils Presentation Highlighting Advances in AI-Driven Drug Discovery and Biotherapeutics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunoPrecise Antibodies Ltd. Unveils Presentation Highlighting Advances in AI-Driven Drug Discovery and Biotherapeutics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmunoPrecise Antibodies Ltd. has presented its latest advancements and financial highlights. The company is a leading provider of biotherapeutic research and technology services, with a focus on antibody discovery and development. Notably, ImmunoPrecise has partnered with 19 of the top 20 global pharma companies and holds 25 patents. The company boasts a strong financial standing with C$12.9M in cash and no debt, maintaining a low burn rate of approximately C$1.2M per quarter. BioStrand, a part of ImmunoPrecise, has demonstrated rapid revenue growth and high gross margins, significantly contributing to the company's overall performance. The LENSai platform, acquired through BioStrand, enhances capabilities in developing new therapies and diagnostics, offering advanced data analysis and optimization of antibody sequences. The platform's HYFT technology further improves data processing efficiency, searching through extensive multi-omics databases at unprecedented speeds. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunoPrecise Antibodies Ltd. Unveils Presentation Highlighting Advances in AI-Driven Drug Discovery and Biotherapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunoPrecise Antibodies Ltd. Unveils Presentation Highlighting Advances in AI-Driven Drug Discovery and Biotherapeutics\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-18 21:19</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunoPrecise Antibodies Ltd. Unveils Presentation Highlighting Advances in AI-Driven Drug Discovery and Biotherapeutics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmunoPrecise Antibodies Ltd. has presented its latest advancements and financial highlights. The company is a leading provider of biotherapeutic research and technology services, with a focus on antibody discovery and development. Notably, ImmunoPrecise has partnered with 19 of the top 20 global pharma companies and holds 25 patents. The company boasts a strong financial standing with C$12.9M in cash and no debt, maintaining a low burn rate of approximately C$1.2M per quarter. BioStrand, a part of ImmunoPrecise, has demonstrated rapid revenue growth and high gross margins, significantly contributing to the company's overall performance. The LENSai platform, acquired through BioStrand, enhances capabilities in developing new therapies and diagnostics, offering advanced data analysis and optimization of antibody sequences. The platform's HYFT technology further improves data processing efficiency, searching through extensive multi-omics databases at unprecedented speeds. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科學工具和服務","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDL3zq300:1","article_id":"2544970408","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544970408","pubTimestamp":1750252782,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ImmunoPrecise Antibodies Ltd. has presented its latest advancements and financial highlights. The company is a leading provider of biotherapeutic research and technology services, with a focus on antibody discovery and development. Notably, ImmunoPrecise has partnered with 19 of the top 20 global pharma companies and holds 25 patents. The company boasts a strong financial standing with C$12.9M in cash and no debt, maintaining a low burn rate of approximately C$1.2M per quarter. BioStrand, a part of ImmunoPrecise, has demonstrated rapid revenue growth and high gross margins, significantly contributing to the company's overall performance. The LENSai platform, acquired through BioStrand, enhances capabilities in developing new therapies and diagnostics, offering advanced data analysis and optimization of antibody sequences. The platform's HYFT technology further improves data processing efficiency, searching through extensive multi-omics databases at unprecedented speeds. You can access ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务"},"translate_title":"ImmunoPrecise Antibodies Ltd.发布演示文稿，重点介绍人工智能驱动的药物发现和生物治疗学的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPA":0.9},"content_text":"ImmunoPrecise Antibodies Ltd. Unveils Presentation Highlighting Advances in AI-Driven Drug Discovery and Biotherapeutics\n    \n\n        ImmunoPrecise Antibodies Ltd. has presented its latest advancements and financial highlights. The company is a leading provider of biotherapeutic research and technology services, with a focus on antibody discovery and development. Notably, ImmunoPrecise has partnered with 19 of the top 20 global pharma companies and holds 25 patents. The company boasts a strong financial standing with C$12.9M in cash and no debt, maintaining a low burn rate of approximately C$1.2M per quarter. BioStrand, a part of ImmunoPrecise, has demonstrated rapid revenue growth and high gross margins, significantly contributing to the company's overall performance. The LENSai platform, acquired through BioStrand, enhances capabilities in developing new therapies and diagnostics, offering advanced data analysis and optimization of antibody sequences. The platform's HYFT technology further improves data processing efficiency, searching through extensive multi-omics databases at unprecedented speeds. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief on June 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}